Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Motpoly Xr Generic Name & Formulations
Legal Class
General Description
Pharmacological Class
How Supplied
XR caps—60
Manufacturer
Generic Availability
NO
Mechanism of Action
The precise mechanism by which Motpoly XR exerts its antiepileptic effects in humans remains to be fully elucidated. In vitro electrophysiological studies have shown that lacosamide selectively enhances slow inactivation of voltage-gated sodium channels, resulting in stabilization of hyperexcitable neuronal membranes and inhibition of repetitive neuronal firing.
Motpoly Xr Indications
Indications
Treatment of partial-onset seizures in adult and pediatric patients weighing ≥50kg.
Motpoly Xr Dosage and Administration
Adult
Swallow whole. ≥17yrs (monotherapy): initially 200mg once daily; (adjunctive therapy): initially 100mg once daily; may increase at weekly intervals by 100mg/day. Maintenance dose: (monotherapy): 300–400mg once daily; (adjunctive): 200–400mg once daily. Dosages >400g/day were not more effective. Conversion from a single antiepileptic to Motpoly XR monotherapy: wait until the therapeutic dose is achieved and given for at least 4 days before withdrawing concomitant antiepileptic; should withdraw gradually over at least 6 weeks. Severe renal impairment (CrCl <30mL/min), ESRD, mild to moderate hepatic impairment: max 300mg; if concomitant strong CYP3A4/CYP2C9 inhibitors: may need dose reduction. Consider supplemental dose (up to 50%) after hemodialysis. Avoid abrupt cessation (withdraw over ≥1 week).
Children
<50kg: not established. Swallow whole. ≥50kg: initially 100mg once daily; may increase at weekly intervals by 100mg/day. Maintenance dose: (monotherapy): 300–400mg once daily; (adjunctive): 200–400mg once daily. Conversion from a single antiepileptic to Motpoly XR monotherapy: wait until the therapeutic dose is achieved and given for at least 4 days before withdrawing concomitant antiepileptic; should withdraw gradually over at least 6 weeks. Severe renal impairment (CrCl <30mL/min), ESRD, mild to moderate hepatic impairment: max 300mg; if concomitant strong CYP3A4/CYP2C9 inhibitors: may need dose reduction. Consider supplemental dose (up to 50%) after hemodialysis. Avoid abrupt cessation (withdraw over ≥1 week).
Motpoly Xr Contraindications
Not Applicable
Motpoly Xr Boxed Warnings
Not Applicable
Motpoly Xr Warnings/Precautions
Warnings/Precautions
Severe hepatic impairment: not recommended. Increased risk of suicidal thinking and behavior; monitor for clinical worsening or unusual changes. Cardiac conduction disturbances (eg, marked 1st-, 2nd-degree or higher AV block, sick sinus syndrome unless paced), sodium channelopathies (eg, Brugada Syndrome), or severe cardiac disease (eg, myocardial ischemia, HF, structural heart disease); obtain ECG before therapy and after titration. Risk for atrial arrhythmias esp. in those with diabetic neuropathy and/or cardiovascular disease. Elderly. Pregnancy. Nursing mothers: monitor infants.
Motpoly Xr Pharmacokinetics
Absorption
Absolute bioavailability: ~100%. Peak plasma concentrations: reached in 7 hours (after oral admin). Steady state plasma concentrations: achieved after 4 days.
Distribution
Volume of distribution: ~0.67 L/kg. Plasma protein bound: <15%.
Elimination
Renal (~95%), fecal (<0.5%). Half-life: ~13 hours.
Motpoly Xr Interactions
Interactions
Caution with concomitant drugs that affect cardiac conduction (eg, sodium or potassium channel blockers, β-blockers, CCBs) or prolong PR interval. May be potentiated by strong CYP3A4/2C9 inhibitors in patients with renal or hepatic impairment. May cause CNS depression if concomitant with alcohol and other CNS depressants.
Motpoly Xr Adverse Reactions
Adverse Reactions
Diplopia, dizziness, headache, nausea, blurred vision, diarrhea, fatigue, ataxia, somnolence, tremor; PR interval prolongation, AV block, syncope, DRESS/multi-organ hypersensitivity (discontinue if occurs).
Motpoly Xr Clinical Trials
See Literature
Motpoly Xr Note
Not Applicable
